Watson bio withdrawn 3 vaccine clinical application research and development ability to squeeze "moisture"

September 7, Watson Biology (quotes, Inquisition) (300142. SZ) issued a notice claiming that three vaccines were withdrawn from domestic clinical research applications, which were not the first time the company withdrew. The list of research items disclosed in the company's prospectus has been "shrinking" since the listing. September 9, the company's shares fell 3.74%, the decline ranked fourth in the pharmaceutical sector.　　Financial profit Po, the current savings rate increased 1000% September 7, Watson's biological release announced the withdrawal of "adsorption of cell-free hundred-white rupture, recombinant hepatitis B, Haemophilus influenzae-type influenza vaccine" in the domestic clinical research application. The company said the development of the above three vaccines is mainly based on overseas market demand, however, since the combined vaccine is inconsistent with the current immunization program of current immunization program in China, it is possible to carry out clinical trials in China, which may make the combination vaccine more uncertain in domestic drug registration.　　Thus the company decided to withdraw the application for clinical research in the country.　　Some people in the industry are not agree with the company, "about three vaccines, if the reasons for the policy environment, why did not do careful consideration, may or because the results of clinical trials are not very grasp."　　In fact, this is not the first time the company has withdrawn its vaccine project. March 2012, the company announced that because of the 13-valent pneumococcal polysaccharide combined with the vaccine in effect can completely cover the 9-valent pneumococcal polysaccharide combined vaccine (hereinafter referred to as "9-price pneumonia vaccine"), the State administration of drugs and Drug Administration agreed to withdraw the latter clinical trial approval application.　　In April 2012, the company also announced the discontinuation of the CPG rabies vaccine, the MA cheek wind vaccine and the pika nasal mucosal immune influenza split vaccine three project development.　　A vaccine expert told reporters, "and the 9 price and 13-valent pneumonia vaccine, similar to the alternative, the company withdrew the adsorption of no cell hundred-white broken joint, and the company another in the research of the absorption of tetanus vaccine between the same alternative." The company was listed in November 2010, at that time to 95 yuan offering price, 133.8 times times the issuance of P/E trading board, broke the record of the current A-share history, a total of 2.375 billion yuan to raise capital, over 1.8 billion yuan, a temporary scenery unlimited.　　The most important reason that the company receives the market hot holds is that the company has set up the image of "many projects in the research, the development ability domestic leading, the growth potential is very considerable", the research and development ability is regarded as the company's core competitiveness. Company in the prospectus, said the company 9 years to develop 13 vaccine products, and another 10 products are undergoing preclinical research, has formed a "rich in quantity, excellent structure" of the product reserves, research and development strength of the domestic leading.　　But in the two years of listing, share prices have been falling, in addition to the decline in performance growth after the company listed, but also because the company's research and development capabilities are constantly questioned.　　The ongoing withdrawal of research and development projects worries the market, and how much water does the company have in its long list of vaccine projects? The vaccine expert told the reporter, "the company in the research vaccine, there are at least two pairs of is belong to each other,Products that can be merged into similar terms are lyophilized A, C group meningococcal polysaccharide vaccine and lyophilized A, C, W135, y meningococcal polysaccharide vaccine, recombinant (Hanson yeast) hepatitis B vaccine and CPG adjuvant enhanced hepatitis B vaccine.　　"In addition, the withdrawal of the absorption of cell-free hundred white break is a triple vaccine, the company is still in the research of the varieties of four, five vaccines, research and development more difficult," the expert also pointed out. Data show that 2010, 2011, 2012 and the first half of 2013, the company's net profit year-on-year growth rate of 102%, 34%, 8.6% and 28.7%, the performance growth rate is falling, the company is still in the performance of the process.